TY - JOUR
T1 - Loss of Constitutional Heterozygosity in Colorectal Tumors from Patients with Familial Polyposis Coli and Those with Nonpolyposis Colorectal Carcinoma
AU - Sasaki, Masayuki
AU - Okamoto, Mieko
AU - Sato, Chieko
AU - Sugio, Kenii
AU - Soejima, Jun Ichi
AU - Iwama, Takeo
AU - Ikeuchi, Tatsuro
AU - Tonomura, Akira
AU - Miyaki, Michiko
AU - Sasazuki, Takehiko
PY - 1989/8/15
Y1 - 1989/8/15
N2 - Familial polyposis coli (FPC) is an autosomal dominant tumorigenic disorder, the major gene of which is mapped to chromosome 5q. We searched for a gene loss in colorectal tumors from FPC patients, as related to tumorigenesis by inactivation of tumor suppression genes, using restriction fragment length polymorphism analysis. The findings were compared with those in the case of nonpolyposis colorectal carcinomas (NPCC). We examined specimens from 39 FPC patients, including 21 adenocarcinomas and 49 adenomas, and 23 colorectal carcinomas from 22 NPCC patients. For this, we used 53 polymorphic DNA markers on all autosomes. Frequent loss of heterozygosity in colorectal carcinoma from FPC patients was observed on chromosomes 5 (24%), 14 (20%), 17 (31%), 18 (40%), and 22 (35%) and also on chromosomes 5 (32%), 14 (30%), 17 (27%), 18 (20%), and 22 (19%) in NPCC. Although loss of heterozygosity in adenoma from FPC patients was observed on nine chromosomes, the frequencies were less than 7%. As we fractionated tumors only macroscopically, actual frequencies of loss of heterozygosity are probably somewhat higher. However, these results do suggest that tumor suppression genes for colorectal carcinoma may locate on chromosomes 5,14, 17,18, and 22 and that they may play a critical role in carcinogenesis in both FPC and NPCC patients.
AB - Familial polyposis coli (FPC) is an autosomal dominant tumorigenic disorder, the major gene of which is mapped to chromosome 5q. We searched for a gene loss in colorectal tumors from FPC patients, as related to tumorigenesis by inactivation of tumor suppression genes, using restriction fragment length polymorphism analysis. The findings were compared with those in the case of nonpolyposis colorectal carcinomas (NPCC). We examined specimens from 39 FPC patients, including 21 adenocarcinomas and 49 adenomas, and 23 colorectal carcinomas from 22 NPCC patients. For this, we used 53 polymorphic DNA markers on all autosomes. Frequent loss of heterozygosity in colorectal carcinoma from FPC patients was observed on chromosomes 5 (24%), 14 (20%), 17 (31%), 18 (40%), and 22 (35%) and also on chromosomes 5 (32%), 14 (30%), 17 (27%), 18 (20%), and 22 (19%) in NPCC. Although loss of heterozygosity in adenoma from FPC patients was observed on nine chromosomes, the frequencies were less than 7%. As we fractionated tumors only macroscopically, actual frequencies of loss of heterozygosity are probably somewhat higher. However, these results do suggest that tumor suppression genes for colorectal carcinoma may locate on chromosomes 5,14, 17,18, and 22 and that they may play a critical role in carcinogenesis in both FPC and NPCC patients.
UR - http://www.scopus.com/inward/record.url?scp=0024382335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024382335&partnerID=8YFLogxK
M3 - Article
C2 - 2568169
AN - SCOPUS:0024382335
SN - 0008-5472
VL - 49
SP - 4402
EP - 4406
JO - Cancer Research
JF - Cancer Research
IS - 16
ER -